In turn, LOX regulation of EGFR also occurs, and was found, in primary and metastatic breast cancer cells, to be linked to the suppression of TGFβ1 signaling with the involvement of HTRA1, leading to increased expression of the EGF-like domain-containing MATN2 that traps EGFR at the cell surface, as part of its activation by EGF [13]. The gene discussed is EGFR; the disease is breast carcinoma.